CL2012001271A1 - Combinacion que comprende un inhibidor de smoothened que es 2-(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2`]-bipirazinil-5`-il]-propan-2-ol y un inhibidor de mtor; uso para tratar el cancer. - Google Patents

Combinacion que comprende un inhibidor de smoothened que es 2-(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2`]-bipirazinil-5`-il]-propan-2-ol y un inhibidor de mtor; uso para tratar el cancer.

Info

Publication number
CL2012001271A1
CL2012001271A1 CL2012001271A CL2012001271A CL2012001271A1 CL 2012001271 A1 CL2012001271 A1 CL 2012001271A1 CL 2012001271 A CL2012001271 A CL 2012001271A CL 2012001271 A CL2012001271 A CL 2012001271A CL 2012001271 A1 CL2012001271 A1 CL 2012001271A1
Authority
CL
Chile
Prior art keywords
inhibitor
bipyrazinyl
pyridazin
propan
tetrahydro
Prior art date
Application number
CL2012001271A
Other languages
English (en)
Inventor
Silvia Buonamici
Marion Dorsch
Echeverria Carlos Garcia
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43384585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001271(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2012001271A1 publication Critical patent/CL2012001271A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2012001271A 2009-11-18 2012-05-16 Combinacion que comprende un inhibidor de smoothened que es 2-(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2`]-bipirazinil-5`-il]-propan-2-ol y un inhibidor de mtor; uso para tratar el cancer. CL2012001271A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26234209P 2009-11-18 2009-11-18
US29203210P 2010-01-04 2010-01-04

Publications (1)

Publication Number Publication Date
CL2012001271A1 true CL2012001271A1 (es) 2012-10-12

Family

ID=43384585

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001271A CL2012001271A1 (es) 2009-11-18 2012-05-16 Combinacion que comprende un inhibidor de smoothened que es 2-(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2`]-bipirazinil-5`-il]-propan-2-ol y un inhibidor de mtor; uso para tratar el cancer.

Country Status (17)

Country Link
US (2) US20120232087A1 (es)
EP (1) EP2501370A1 (es)
JP (1) JP2013511526A (es)
KR (1) KR20120107962A (es)
CN (2) CN102665700A (es)
AU (1) AU2010322114B2 (es)
BR (1) BR112012011823A2 (es)
CA (1) CA2781210A1 (es)
CL (1) CL2012001271A1 (es)
IL (1) IL219636A0 (es)
MA (1) MA33739B1 (es)
MX (1) MX2012005695A (es)
NZ (1) NZ599964A (es)
RU (1) RU2012125152A (es)
TN (1) TN2012000205A1 (es)
WO (1) WO2011062939A1 (es)
ZA (1) ZA201203325B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2781287C (en) 2009-11-18 2018-07-31 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
JP2014516549A (ja) * 2011-06-02 2014-07-17 ノバルティス アーゲー ヘッジホッグ阻害剤療法のためのバイオマーカー
WO2013106812A1 (en) * 2012-01-12 2013-07-18 Board Of Regents, The University Of Texas System Personalized medicine for the prediction of therapy targeting the hedgehog pathway
BR112015010186A2 (pt) * 2012-11-05 2017-07-11 Nant Holdings Ip Llc sulfonamida cíclica contendo derivados como inibidores da via de sinalização de hedgehog
CN103524535B (zh) * 2013-10-16 2016-07-13 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物
CA3078769A1 (en) 2017-10-27 2019-05-02 Boehringer Ingelheim International Gmbh Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
JP2021530463A (ja) * 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
WO2020061584A1 (en) * 2018-09-21 2020-03-26 Msb Holdings, Inc. Taste-masked dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
PL1954699T3 (pl) 2005-11-22 2013-01-31 Kudos Pharm Ltd Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR
UA93548C2 (uk) * 2006-05-05 2011-02-25 Айерем Елелсі Сполуки та композиції як модулятори хеджхогівського сигнального шляху
SI2057156T1 (sl) 2006-08-23 2017-06-30 Kudos Pharmaceuticals Limited Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR
UA100684C2 (uk) * 2007-03-15 2013-01-25 Новартіс Аг Похідні бензилу та піридинілу як модулятори сигнального шляху hedgehog
MX2009013273A (es) * 2007-06-07 2010-01-25 Irm Llc Derivados de bifenil-carboxamida como moduladores de la senda de hedgehog.
US8153633B2 (en) * 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009112266A1 (en) * 2008-03-12 2009-09-17 Ludwig-Maximilians-Universität Active substance combination with gemcitabine for the treatment of epithelial cancer
AU2009241561B2 (en) * 2008-04-29 2013-05-16 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors

Also Published As

Publication number Publication date
KR20120107962A (ko) 2012-10-04
EP2501370A1 (en) 2012-09-26
NZ599964A (en) 2014-08-29
BR112012011823A2 (pt) 2019-09-24
RU2012125152A (ru) 2013-12-27
AU2010322114B2 (en) 2014-07-31
CN104224791A (zh) 2014-12-24
US20150025074A1 (en) 2015-01-22
MX2012005695A (es) 2012-06-13
AU2010322114A1 (en) 2012-05-31
ZA201203325B (en) 2013-01-30
TN2012000205A1 (en) 2013-12-12
IL219636A0 (en) 2012-07-31
JP2013511526A (ja) 2013-04-04
MA33739B1 (fr) 2012-11-01
CA2781210A1 (en) 2011-05-26
WO2011062939A1 (en) 2011-05-26
US20120232087A1 (en) 2012-09-13
CN102665700A (zh) 2012-09-12

Similar Documents

Publication Publication Date Title
CL2012001271A1 (es) Combinacion que comprende un inhibidor de smoothened que es 2-(r)-4-(6-bencil-4,5-dimetil-piridazin-3-il)-2-metil-3,4,5,6-tetrahidro-2h-[1,2`]-bipirazinil-5`-il]-propan-2-ol y un inhibidor de mtor; uso para tratar el cancer.
CL2012003643A1 (es) Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension.
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
CO6842016A2 (es) Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer
CL2008000510A1 (es) Compuestos conjugados farmaco-ligandos, que se unen a citotoxinas potentes; composicion farmaceutica; y uso para retardar o detener el crecimiento de un tumor en un mamifero.
CL2014001062A1 (es) Metodo para tratar tumores del estroma gastrointestinal que comprende el uso de un inhibidor de c-hit y un inhibidor de pi3k o fgfr y combinacion que comprende a los compuestos.
CL2015000294A1 (es) Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa.
CL2008001038A1 (es) Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano
DK2139483T3 (da) Kombinationsterapier, der omfatter en quinoxalin-inhibitor af PI3K-alfa, til anvendelse til behandling af cancer
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI1013698A2 (pt) métodos para tratamento com o uso de terapia de combinação
NO20090079L (no) Arylsulfonamider med analgesisk virkning
CL2013000801A1 (es) Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
CL2013001324A1 (es) Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.
BRPI0822012A2 (pt) Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0913175A2 (pt) artigo antibalístico, e, uso do mesmo.
CL2013002905A1 (es) Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares.
BR112012004851A2 (pt) agente para o tratamento e/ou profilaxia de um distúrbio de humor, derivado de tiazol, e, uso do derivado de tiazol
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CL2015001564A1 (es) Composición que comprende una triazina y su uso en el tratamiento intramuscular de coccidiosis o enfermedad protozoaria relacionada, en un mamífero no humano.